Stock Screener App

무료 -

1.90

3.26% 0.06

Vyne Therapeutics Inc (VYNE)

개요 뉴스 가격 이력 Financials 토론 예측 주식 분할

Vyne Therapeutics Inc 주식(VYNE)의 최신 뉴스

HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World

VYNE reports positive early trial results for inflammation drug - Investing.com

VYNE reports positive early trial results for inflammation drug - Investing.com India

VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202 - TipRanks

VYNE reports positive early trial results for inflammation drug By Investing.com - Investing.com UK

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan

VYNE Therapeutics to Participate in September Investor Conferences - StockTitan

VYNE Therapeutics sees cash runway through end of 2025 - TipRanks

VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Reaffirmed by HC Wainwright - Defense World

VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year - TipRanks

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan

VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024 - InvestorPlace

Virtu Financial LLC Takes Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.5% - Defense World

VYNE Therapeutics secures UK patent for inflammation drug - Investing.com

Latest Patent Grant Is Driving VYNE Therapeutics Stock Higher Today - News IMC

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan

One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year - Yahoo Finance

VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - citybiz

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - StockTitan

How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2% - Yahoo News Malaysia

VYNE Therapeutics Insiders Are Down US$27k But Regain Some Losses - Simply Wall St

VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease - Dermatology Times

VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 22.2% in June - Defense World

Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket - Quantisnow

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - StockTitan

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewswire Inc.

VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo News UK

Eventide Asset Management LLC Takes $3.25 Million Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

H.C. Wainwright eyes VYNE stock as Phase 1a trial commences - Investing.com India

H.C. Wainwright eyes VYNE stock as Phase 1a trial commences By Investing.com - Investing.com Canada

H.C. Wainwright eyes VYNE stock as Phase 1a trial commences By Investing.com - Investing.com Australia

H.C. Wainwright eyes VYNE stock as Phase 1a trial commences By Investing.com - Investing.com

VYNE Therapeutics (NASDAQ:VYNE) Rating Reiterated by HC Wainwright - Defense World

Analyst Scoreboard: 4 Ratings For VYNE TherapeuticsVYNE Therapeutics (NASDAQ:VYNE) - Benzinga

Fostering Mentorship and Support in Early-Stage Physician Assistants - Dermatology Times

VYNEVYNE Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

VYNE Therapeutics Initiates Phase 2b Trial of BET Inhibitor VYN201 for Vitiligo - Dermatology Times

VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - Defense World

PODCAST: From Infection to InnovationThe Turn Therapeutics Story - Dermatology Times

All You Need to Know About VYNE Therapeutics Inc. (VYNE) Rating Upgrade to Buy - Yahoo Movies UK

Short Interest in Volcon, Inc. (NASDAQ:VLCN) Grows By 46.0% - Defense World

Can VYNE Therapeutics Inc. (VYNE) Climb 415.04% to Reach the Level Wall Street Analysts Expect? - Yahoo Singapore News

Verrica Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations - Simply Wall St

VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update - Defense World

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates - Zacks Investment Research

VYNE Therapeutics'(NASDAQ:VYNE) Share Price Is Down 11% Over The Past Year. - Yahoo Movies UK

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates - Zacks Investment Research

VYNE Therapeutics Provides Updates on VYN201 for Nonsegmental Vitiligo and VYN202 for Inflammatory Diseases - Dermatology Times

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research

Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and VYNE Therapeutics (NASDAQ:VYNE) - Defense World

VYNE Therapeutics receives FDA approval for trial of VYN202 - Clinical Trials Arena

VYNE Therapeutics gets FDA nod for new drug trial - Investing.com

VYNE Therapeutics gets FDA nod for new drug trial - Investing.com India

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation - Simply Wall St

VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

$26.56

1.26%

$196.11

1.22%

$28.98

9.71%

$69.58

1.94%

$127.27

3.16%

$538.23

0.08%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | Open in MarketWatch | Open in EDGAR | Open in Reuters